<DOC>
	<DOCNO>NCT00162487</DOCNO>
	<brief_summary>Several study indicate albuterol administer either intravenously inhalation significantly reduce plasma potassium concentration patient suffer chronic renal failure.In conjunction decrease potassium concentration modest rise glucose concentration usually note . These metabolic effect characterize rapid onset occur early 3-5 minute follow salbutamol administration last least 1 hour . The role play ß2AR polymorphism determine bronchial vascular response ß2AR agonist drug , confirm several study . The purpose present study examine possible causal relationship genetically base alteration structure ß2AR metabolic effect inhale albuterol .</brief_summary>
	<brief_title>Genetic Determinants Hypokalemic Hyperglycemic Effect Albuterol Inhalation</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperkalemia</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>patient regularly attend nephrological clinic dialysis unit persistent potassium concentration 5 mEq/L 1 . Patients suffer active ischemic heart disease 2 . Patient recent history arrhythmia 3 . Patients treat regularly ß blocker 4 . Patients treat regularly salbutamol ß2AR agonist 5 . Patients suffer persistent tachycardia ( pulse &gt; 100 beats/min ) 6 . Patients hemodynamically unstable 7 . Patients suffer acute illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>